TerminatedNot Applicable

A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy

Stopped: Insufficient Staff

United States21 participantsStarted 2023-03-21

Plain-language summary

This clinical trial looks at the use of an internet-based application (app) intervention in improving adherence to endocrine therapy (ET) among patients with early stage hormone receptor-positive HER2-negative breast cancer. ET can significantly reduce the return of the cancer in patients who are compliant with their treatment regimen. Despite this, adherence to ET is poor due to side effects, lack of social support and timely access to clinicians, and poor patient understanding of the necessity and effectiveness of the therapy. An internet-based app may help patients improve their adherence to ET by providing reminders, side effect mitigation strategies available in the educational videos and from contacting providers/ nurse on the research team directly via the app.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Early-stage hormone receptor positive, HER2-negative breast cancer who have completed all recommended (neo)adjuvant chemotherapy, surgery and/or radiation therapy * Age \>= 18 * Started on an aromatase inhibitor or Tamoxifen within less than or equal to six months prior to time of enrollment * Access to internet from a desktop or a smartphone * Ability to speak English Exclusion Criteria: * Patients who are her2 neu positive

What they're measuring

Feasibility (Acceptability)

Timeframe: Up to 1 year

Feasibility (Compliance)

Timeframe: Up to 1 year

Trial details

NCT IDNCT05488145

SponsorEmory University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-10

View on ClinicalTrials.gov More Anatomic Stage I Breast Cancer AJCC v8 trials